Zydus receives USFDA approval for Cariprazine Capsules

12 Sep 2022 , 03:46 PM

Zydus Lifesciences U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received final approval from the United States Food and Drug Administration (USFDA) to market Cariprazine Capsules, USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg (USRLD: VRAYLAR?). Zydus was one of the first ANDA applicants to submit a substantially complete ANDA with a paragraph IV certification for Cariprazine Capsules, 1.5 mg, 3 mg, 4.5 mg, and 6 mg and thereforeis eligible for 180 days of shared generic drug exclusivity for Cariprazine Capsules, 1.5 mg, 3 mg, 4.5 mg, and 6 mg. Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. The drug will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. Cariprazine Capsules had annual sales of USD 2.39 bn in the United States according to IQVIA MAT July 2022.Powered by Capital Market – Live News